NCT06423781

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Major Depressive Disorder (MDD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 233 (actual)
• Sponsor: Biohaven Therapeutics Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	BHV-7000	BHV-7000 75 mg taken once daily

Timeline

• Start date: 2024-08-01
• Primary completion: 2026-03-18
• Completion: 2026-03-18
• First posted: 2024-05-21
• Last updated: 2026-04-01

Locations

66 sites across 1 country: United States

Regulatory

• FDA-regulated drug study